HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.
Psychedelics
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Cybin Inc receives its Notice of Allowance from the USPTO with respect to its patent for CYB004.
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
atai partner, Recognify Life Sciences, reports positive Phase 2a results in treating Cognitive Impairment Associated with Schizophrenia.
MINDCURE (CSE: MCUR) (OTCQX: MCURF) Appoints Dr. Doron Sagman as Chief Medical Officer
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”)
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.
The Military Mental Health Crisis, A National Tragedy: Part I
The ongoing and worsening mental health crisis in the U.S. military is a national tragedy and a national disgrace. Part I reveals the ugly Big Picture.
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.
MINDCURE's iSTRYM Platform: Psychedelics Penetration Is Only The Beginning
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
More Outstanding Results With Psychedelics Research, Even More Outstanding Value For Investors
GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Mydecine files a detailed patent application covering "multiple families of psilocin analogs."
Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders
Novamind's new Salt Lake City clinic will specialize in treating substance abuse disorders.
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research reports its Q3 for 2021 and announces VERY successful results from its Phase 2a trial for Treatment Resistant Depression (TRD).